Opendata, web and dolomites

EPIPHARM SIGNED

Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIPHARM project word cloud

Explore the words cloud of the EPIPHARM project. It provides you a very rough idea of what is the project "EPIPHARM" about.

poor    empiric    despite    mentioned    epigenotyping    taxane    undergoing    image    world    human    tumor    diagnoses    disease    therapy    innovative    feasibility    tool    grant    optimize    demonstrating    technologies    recommended    treatments    tools    treatment    diagnosis    personalized    months    modest    loci    pharmacological    primary    cancers    clinical    pirnas    epinorc    ncrnas    reported    introduction    epigenetic    throughput    proof    providers    methylation    disruption    benefit    usually    licensed    ncrna    first    cup    sensitivity    cancer    50    anonymous    rna    fingerprint    commercially    cpg    regarding    site    chemotherapy    heterogeneous    health    lincrnas    outcome    approximately    presentation    pharmacogenetics    final    pattern    allowed    coding    origin    metastatic    poc    interesting    unknown    platinum    idea    assay    company    rnas    dismal    showed    immunohistochemistry    snornas    drug    epigenetics    comprise    death    regimens    group    guide    variety    prognoses    plan    profile    extremely    dna    micrornas    six    epicup    successful    gemcitabine    patients    validation    erc       cups    ucrs    epipharm   

Project "EPIPHARM" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE 

Organization address
address: AVENIDA GRAN VIA HOSPITALET 199-203
city: L'HOSPITALET DE LLOBREGAT
postcode: 8908
website: www.idibell.cat

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 149˙345 €
 EC max contribution 149˙345 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2018-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE ES (L'HOSPITALET DE LLOBREGAT) coordinator 119˙345.00
2    XENOPAT SL ES (HOSPITALET DE LLOBREGAT) participant 30˙000.00

Map

 Project objective

The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify a drug sensitivity fingerprint based in the DNA methylation profile of non-coding RNA (ncRNA) loci. CUPs are a heterogeneous group of cancers defined by the presence of metastatic disease with no identified primary tumor at presentation. The CUP outcome is extremely poor with an expected death within the first six months of the diagnosis. CUP has been reported to comprise approximately 5% of all cancer cases in the world. Despite the introduction of new image technologies and immunohistochemistry methods, more than 50% of CUPs remain anonymous regarding their primary tumor site of origin and, as mentioned, their prognoses are dismal. For most patients with CUP, recommended treatments involves just empiric chemotherapy, usually with a taxane/platinum or gemcitabine/platinum regimens that achieve the described modest clinical benefit. Thus, it is necessary to have better tools to guide the pharmacological treatment of CUP cases. As part of the ERC Advanced Grant “Epigenetic Disruption on Non-Coding RNAs in Human Cancer” (EPINORC) we identified CpG methylation changes in a wide variety of ncRNAs (microRNAs, lincRNAs, T-UCRs, snoRNAs, piRNAs...) that showed a tumor-type specific pattern that has allowed the successful development of the EPICUP assay for the diagnoses of CUPs that it has been licensed and it is undergoing final clinical validation. In the current EPIPHARM Proof of Concept (PoC) proposal, we plan to optimize a ncRNA DNA methylation assay that includes a user-friendly and cost effective approach to improve the therapy of CUP cases by providing a more personalized drug treatment to an extent that will make it interesting commercially for the health providers and their associated company partners.

 Publications

year authors and title journal last update
List of publications.
2018 Michäel Duruisseaux, Anna Martínez-Cardús, Maria E Calleja-Cervantes, Sebastian Moran, Manuel Castro de Moura, Veronica Davalos, David Piñeyro, Montse Sanchez-Cespedes, Nicolas Girard, Marie Brevet, Etienne Giroux-Leprieur, Coraline Dumenil, Monica Pradotto, Paolo Bironzo, Enrica Capelletto, Silvia Novello, Alexis Cortot, Marie-Christine Copin, Niki Karachaliou, Maria Gonzalez-Cao, Sergio Peralta, Luis M Montuenga, Ignacio Gil-Bazo, Iosune Baraibar, Maria D Lozano, Mar Varela, Jose C Ruffinelli, Ramon Palmero, Ernest Nadal, Teresa Moran, Lidia Perez, Immaculada Ramos, Qingyang Xiao, Agustin F Fernandez, Mario F Fraga, Marta Gut, Ivo Gut, Cristina Teixidó, Noelia Vilariño, Aleix Prat, Noemi Reguart, Amparo Benito, Pilar Garrido, Isabel Barragan, Jean-François Emile, Rafael Rosell, Elisabeth Brambilla, Manel Esteller
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis
published pages: 771-781, ISSN: 2213-2600, DOI: 10.1016/S2213-2600(18)30284-4
The Lancet Respiratory Medicine 6/10 2019-04-03
2017 Sebastián Moran, Anna Martinez-Cardús, Stergios Boussios, Manel Esteller
Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary
published pages: 682-694, ISSN: 1759-4774, DOI: 10.1038/nrclinonc.2017.97
Nature Reviews Clinical Oncology 14/11 2019-04-03
2018 Humberto J. Ferreira, Veronica Davalos, Manuel Castro de Moura, Marta Soler, Montserrat Perez-Salvia, Alberto Bueno-Costa, Fernando Setien, Sebastian Moran, Alberto Villanueva, Manel Esteller
Circular RNA CpG island hypermethylation-associated silencing in human cancer
published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.25673
Oncotarget 9/49 2019-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIPHARM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIPHARM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

VictPart (2019)

Righting Victim Participation in Transitional Justice

Read More